Supernus Pharmaceuticals (NASDAQ: SUPN- Get a rating) has been updated by equity research analysts from StockNews.com from a “buy” rating to a “strong buy” rating in a note released Friday to investors.
Separately, Piper Sandler raised her price target on Supernus Pharmaceuticals from $33.00 to $38.00 and gave the stock an “overweight” rating in a research note on Wednesday.
Supernus Pharmaceuticals stock performance
NASDAQ:SUPN shares traded down $0.65 during Friday trading hours, hitting $34.39. The stock had a trading volume of 206,464 shares, compared to an average volume of 417,010. Supernus Pharmaceuticals has a 1-year low of $24.95 and a 1-year high of $36.08. The company’s 50-day moving average is $31.48 and its 200-day moving average is $30.26. The stock has a market capitalization of $1.84 billion, a price-earnings ratio of 34.05 and a beta of 1.04.
Supernus Pharmaceuticals (NASDAQ: SUPN- Get a rating) last reported results on Thursday, August 4. The specialty pharmaceutical company reported EPS of $0.14 for the quarter, missing analyst consensus estimates of $0.29 per ($0.15). Supernus Pharmaceuticals had a return on equity of 6.98% and a net margin of 9.12%. The company posted revenue of $170.10 million for the quarter, versus analyst estimates of $164.23 million. In the same quarter a year earlier, the company posted EPS of $0.43. The company’s revenue for the quarter increased 20.4% year over year. Analysts expect Supernus Pharmaceuticals to post EPS of 1.51 for the current year.
Insider Activity at Supernus Pharmaceuticals
A d CRE Income Fund
Earn an attractive 10% dividend yield with minimal downside
Commercial real estate price growth hit historic pace in 2021, find out how the CRE Income Fund pays a 10% annual dividend yield and is a long-term strategy that pays over $25,000 for every 10,000 $ invested over the next ten years.
Separately, CEO Jack A. Khattar sold 39,431 shares of the company in a trade dated Tuesday, August 9. The stock was sold at an average price of $31.15, for a total value of $1,228,275.65. Following the completion of the sale, the CEO now directly owns 724,978 shares of the company, valued at approximately $22,583,064.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, accessible via the SEC website. Separately, CEO Jack A. Khattar sold 39,431 shares of the company in a trade that took place on Tuesday, August 9. The shares were sold at an average price of $31.15, for a total transaction of $1,228,275.65. As a result of the transaction, the CEO now directly owns 724,978 shares of the company, valued at $22,583,064.70. The sale was disclosed in a legal filing with the SEC, accessible via this hyperlink. Additionally, Vice President Tami Tillotson Martin sold 5,000 shares of the company in a trade on Thursday, August 4. The shares were sold at an average price of $32.98, for a total transaction of $164,900.00. Following the completion of the sale, the vice president now owns 87,220 shares of the company, valued at approximately $2,876,515.60. Disclosure of this sale can be found here. Insiders sold a total of 66,733 shares of the company valued at $2,161,863 over the past ninety days. Insiders own 7.99% of the shares of the company.
Hedge funds weigh on Supernus Pharmaceuticals
Several institutional investors have recently increased or reduced their stake in the stock. IndexIQ Advisors LLC purchased a new equity stake in Supernus Pharmaceuticals in the first quarter worth approximately $409,000. Campbell Newman Asset Management Inc. increased its position in Supernus Pharmaceuticals by 2.0% during the 1st quarter. Campbell Newman Asset Management Inc. now owns 22,696 shares of the specialty pharmaceutical company worth $734,000 after purchasing an additional 443 shares during the period. Advisor Resource Council increased its stake in shares of Supernus Pharmaceuticals by 52.8% during the 4th quarter. Advisor Resource Council now owns 78,245 shares of the specialty pharmaceutical company worth $2,281,000 after buying an additional 27,037 shares last quarter. Congress Asset Management Co. MA increased its stake in shares of Supernus Pharmaceuticals by 17.2% in the 1st quarter. Congress Asset Management Co. MA now owns 464,101 shares of the specialty pharmaceutical company valued at $15,000,000 after purchasing an additional 67,996 shares during the period. Finally, Retirement Planning Co of New England Inc. increased its stake in Supernus Pharmaceuticals shares by 1.3% in the first quarter. New England Inc.’s Retirement Planning Co now owns 37,969 shares of the specialty pharmaceutical company valued at $1,227,000 after buying 488 more shares last quarter. Institutional investors and hedge funds own 99.81% of the company’s shares.
Supernus Pharmaceuticals Company Profile
Supernus Pharmaceuticals, Inc, a biopharmaceutical company, is focused on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended-release topiramate indicated for the treatment of epilepsy, as well as for the prophylaxis of migraines; and Oxtellar XR, an extended-release oxcarbazepine for the monotherapy treatment of partial-onset seizures in adults and children aged 6 to 17 years.
See also
This instant news alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to contact@marketbeat.com.
Before you consider Supernus Pharmaceuticals, you’ll want to hear this.
MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes hold…and Supernus Pharmaceuticals was not on the list.
Although Supernus Pharmaceuticals currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the five actions here
